No, increased hunger is not a recognized side effect of tirzepatide
As of the end of May 2023, Medicilon has successfully assisted in the clinical approval of 7 GLP-1 drugs (3 approved by FDA and NMPA1 approved by FDA, NMPA, and TGA) and has multiple GLP-1 projects under development
The effect is gradual and cumulative
Additionally, the 1,25(OH)D/VDR signalling axis plays a pivotal role in modulating the inflammatory pathways associated with cancer by downregulating cyclooxygenase-2 (COX-2), prostaglandin synthesis, and NF-kB signalling
If the point is to adjust the dose or titration pace, that belongs with the treating doctor or endocrinologist managing your tirzepatide therapy
[1] [3] It is important to distinguish between occasional mild light-headedness and persistent or severe symptoms